• The Firm
  • Practices
  • Offices
  • Lawyers
  • Careers
  • Diversity
  • Pro Bono
Browse By Last Name
Search




   
James P. Rouhandeh
Partner
Mr. Rouhandeh is head of Davis Polk’s Litigation Department, representing clients in a variety of civil, criminal and regulatory matters. His practice includes representation of clients in complex civil litigation, including class action securities litigation and shareholder derivative actions, as well as grand jury, SEC and internal investigations. Mr. Rouhandeh has represented a variety of clients in the most well-known investigations and litigations in recent years; his matters typically involve parallel civil, criminal and regulatory proceedings.
Contact
  • New York
    450 Lexington Avenue
    New York, NY 10017
    P: 212-450-4835
    F: 212-701-5835
Bar Admissions
  • State of New York
  • U.S. Supreme Court
  • U.S. Court of Appeals, D.C. Circuit
  • U.S. Court of Appeals, Second Circuit
  • U.S. Court of Appeals, Fourth Circuit
  • U.S. Court of Appeals, Sixth Circuit
  • U.S. Court of Appeals, Seventh Circuit
  • U.S. District Court, W.D. Michigan
  • U.S. District Court, E.D. New York
  • U.S. District Court, S.D. New York
Education
  • B.A., Southern Illinois University, 1984
  • J.D., Harvard Law School, 1987
    • Editor, Harvard Law Review

Work Highlights
Recent Civil Litigation
  • Dismissal with prejudice of all claims against national law firm in connection with the collapse of Allen Stanford-related entities
  • Dismissal with prejudice of class action securities litigation relating to the Libertas CDO
  • Dismissal of all claims in class action securities litigation relating to mortgage pass-through certificates on standing and statute of limitations grounds
  • Representation of senior management of major pharmaceutical company in shareholder derivative action following resolution of federal grand jury investigation
  • Denial of class certification in favor of Morgan Stanley in case in which plaintiffs sought certification of claims of investors in a structured investment vehicle backed by CDOs and RMBS
  • Representation of special committee of the board of major mutual fund in connection with shareholder demand
  • Landmark denial of class certification in favor of Pfizer in MDL in which plaintiffs sought $4.6 billion in alleged damages for payments relating to the off-label use of the prescription drug Neurontin
  • Unanimous reversal by the U.S. Supreme Court in case representing amicus curiae seeking to overturn the application of 21 U.S.C. 843(b) to certain purchasers of controlled substances
  • Representation of Morgan Stanley in multiple litigations relating to mortgage-backed securities
  • Summary judgment awarding actual and consequential damages in favor of Deutsche Bank in a breach of contract action relating to convertible bonds
  • Decertification of a class action brought against Pfizer in Pennsylvania
  • Dismissal of RICO and antitrust claims against Smith & Nephew brought in federal court in New Jersey
  • Dismissal of all claims against J.P. Morgan, Morgan Stanley, Citigroup and Bank of America in the AOL Time Warner MDL securities litigation relating to restatement of earnings following $10 billion bond offering
  • Summary judgment on ’34 Act claims and dismissal of ’33 Act claims brought against TD Securities in federal securities fraud class action brought in federal court in South Carolina following restatement and bankruptcy of Safety Kleen Corp. and indictment of Safety Kleen’s top officers
  • Dismissal of all claims against J.P. Morgan, Citigroup and Bank of America in California state court securities fraud action relating to AOL Time Warner
  • Summary judgment for J.P. Morgan in federal securities class action in federal court in Michigan relating to Perrigo Company, whose stock dropped 40% in a single day shortly after the then-largest IPO in Nasdaq history
  • Dismissal of consumer fraud class action against Pfizer in New York state court
  • Dismissal of all class claims in consumer fraud action against Pfizer in New Mexico state court
  • Summary judgment for Pfizer in a consumer fraud action brought in federal court in North Carolina and West Virginia
Criminal and SEC Investigations

Mr. Rouhandeh’s recent representations include:

  • A broker-dealer in an internal investigation relating to potential insider trading
  • A major pharmaceutical company in a federal grand jury investigation and related matters that resulted in a resolution with the federal government and all 50 states
  • A national law firm in connection with a federal investigation relating to tax opinions
  • The foreign parent of a pharmaceutical company in a federal grand jury investigation
  • A former Worldcom executive in connection with a federal investigation of alleged accounting fraud
  • An individual in a criminal antitrust trial
  • Over 30 partners of a major professional service firm in an SEC investigation
  • A tobacco company in the DOJ’s investigation of the industry
  • An investment bank in an SEC investigation relating to the municipal bond business
  • A former executive of a major pharmaceutical company in a criminal investigation in Japan
Recognition
  • Named an “MVP of the Year” for Securities by Law360 in 2011
  • Multiple matters featured in Financial Times’ Innovative Lawyers in 2010 and 2011
  • Listed as a leading litigation lawyer in Legal Media Group’s Benchmark Litigation: America’s Leading Litigation Firms and Attorneys
  • Recognized by The Legal 500 in connection with white collar criminal defense
Professional History
  • Partner, 1996-present
  • Associate, 1988-1996